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BACKGROUND: The CXC-chemokine expression is linked with colorectal cancer (CRC) progression but their significance in resected
CRC is unclear. We explored the prognostic impact of such expression in stage II and III CRC.
METHODS: Tissue microarrays were constructed from stage II and III CRC biopsies (n¼254), and the expression of CXCL1 and
CXCL8, and their receptors CXCR1 and CXCR2, in malignant and adjacent normal tissue was graded by immunohistochemistry and
was correlated with prognostic factors.
RESULTS: Expression of CXCL1, CXCR1 and CXCR2 was elevated in tumour epithelium relative to normal adjacent tissue (Po0.001).
CXCL8 expression was detectable in the peritumoural inflammatory infiltrate. There was no overall association between CXCL1,
CXCR1 or CXCR2 expression and prognostic endpoints; however, univariate subgroup survival analysis demonstrated an inverse
association between CXCL1 and recurrence-free survival (RFS) in stage III patients (P¼0.041). The CXCL8 positivity in the tumour
infiltrate, however, correlated with earlier disease stage (Po0.001) and improved relapse-free survival across the cohort (Po0.001).
Disease stage (Po0.001) and tumour infiltrate CXCL8 positivity (P¼0.007) were associated with enhanced RFS in multivariate Cox
regression analysis.
CONCLUSION: Autocrine CXC-chemokine signalling may have adverse prognostic effects in early CRC. Conversely, CXCL8 positivity
within the immune infiltrate may have good prognostic significance.
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Colorectal cancer (CRC) remains a major cause of morbidity and
mortality in the Western world, accounting for more than one in
eight newly diagnosed cancers in Europe and over half a million
deaths worldwide annually (Parkin et al, 2005; Ferlay et al, 2007).
Despite this, only half of the patients who undergo potentially
curative surgery survive for 5 years (McArdle and Hole, 2002), and
the challenge of how best to predict prognosis and, thereby
optimise therapy remains. At present, established clinico-patholo-
gical criteria are used to estimate risks of recurrence in stage II and
III disease, and this is routinely used in the selection of patients for
adjuvant systemic therapy following surgical resection. The clinical
outcome of patients who receive such adjuvant treatment can,
however, vary widely, when additional molecular factors are taken
into consideration (Allegra et al, 2003). Identification of novel
prognostic markers is, therefore, vital in improving the prognosis
of this disease.
Chemokines are a large family of chemotactic signalling
molecules that are increasingly attracting attention in the study
of tumourigenic mechanisms within malignant cells and the
tumour microenvironment. They are classified into four broad
groups as follows: C, CC, CXC and CX3C, on the basis of the
position of their cysteine residues (Payne and Cornelius, 2002).
The CXC-chemokines are subdivided further into ELRþ and
ELR , depending on the amino-acid sequence before the first
cysteine residue, and this confers angiogenic or angiostatic
potential on these molecules (Strieter et al, 1995). The best
characterized and prototypic CXC-chemokine is CXCL8, pre-
viously termed interleukin-8 (Rollins, 1997; Beck et al, 1999) and
its biological effects are mediated through two G-protein-coupled
receptors designated CXCR1 and CXCR2. A series of structurally
related CXC-chemokines, including CXCL1, also bind selectively to
the CXCR2 receptor (Ahuja and Murphy, 1996). Both CXCL1 and
CXCL8 are pro-inflammatory mediators, functioning as chemo-
tactic factors for neutrophils (Schroder et al, 1990a).
Multiple clinical studies implicate CXC-chemokines in the
development and progression of CRC. For example, elevated
tumour CXCL8 levels have been associated with increased tumour
size, depth of infiltration, disease stage and liver metastasis, as well
as a shorter overall survival time in CRC (Terada et al, 2005).
Furthermore, the circulating level of CXCL8 in patients’ serum is
higher in more advanced disease stage and in the presence of
bowel wall invasion, liver and/or lung metastasis (Ueda et al, 1994;
Kaminska et al, 2005). The CXCL1 and its receptor CXCR2 are also
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swidely reported to be elevated in CRC, the presence of which
may facilitate CRC tumour progression (Erreni et al, 2009).
However, none of these studies have specifically studied the
expression profile of these chemokines and their receptors in
stage II and III CRC patients who have had potentially curative
resection. Thus, their potential as prognostic markers in this
disease is unclear.
Chemokine signalling not only modulates the function of
cancerous epithelial cells but also serves as an intermediary in
the communication network between tumour cells and the
surrounding stroma. CXC-chemokines have potent effects in
recruiting immune cells to inflammatory sites and CXCL1 and
CXCL8 are both associated with neutrophil recruitment and
activation (Moser et al, 1990; Schroder et al, 1990a). Interestingly,
assessment of the peritumoural inflammatory infiltrate has been
shown to provide prognostic information in CRC (Roxburgh et al,
2009), raising interest in the study of their clinical implications in
this and other solid tumours. Characterisation of CXC-chemokine
expression in these tumour-infiltrating cells is however limited,
whereas the clinical relevance of such expression remains
uncertain.
Our study presents an immunohistochemical profile of the
expression of CXC chemokines and their receptors in 254 stage II
and III CRC tissues. The expression of CXCL1 and CXCL8 and
their receptors CXCR1 and CXCR2 were evaluated within diseased
epithelium and compared with adjacent normal epithelium in
patient-matched samples. Additionally, CXCL8 expression was
characterized throughout the immune infiltrate of the tumours.
We report an increased expression of CXCL1, CXCR1 and CXCR2
in tumour, compared with the surrounding normal epithelium,
providing evidence for enhanced autocrine CXC chemokine
signalling in these cancer cells. Furthermore, we determine a
range of CXCL8-positivity within the immune cell-infiltrate, with
important clinical implications. Accordingly, the significance of
epithelial tumour and tumour immune cell infiltrate expression of
these markers is presented.
MATERIALS AND METHODS
Patients and specimens
Archived formalin-fixed and paraffin-embedded CRC tissue
specimens of 254 patients with stage II and stage III CRC were
retrieved for the study. The specimens were originally obtained
during a randomised controlled phase III clinical trial comparing
16 weeks of De Gramont schedule FU/FA to observation alone in
patients with stage II and III CRC (24). Patients were recruited
from hospitals in Northern Ireland for this study between
March 1994 and February 1997, in compliance with the tenets of
the Declaration of Helsinki. The trial participants gave informed
consent for the use of their tissue for further molecular biomarker
studies, such as this, and ethical approval for this study was
obtained from the local Ethics Committee.
Tissue microarray construction
The study was performed using archival, formalin-fixed paraffin-
embedded colon tumour samples. A total of 254 primary colon
carcinoma cases were selected.
All formalin-fixed paraffin-embedded blocks were sectioned
and stained with H&E and graded by a pathologist (EWK) to
confirm pathological stage and grade of the tumours, and the
relevant tumour areas were marked and used as the donor cores
for TMA construction. The construction was performed using
the Beecher Instruments Tissue Microarrayer (Beecher Instru-
ments, Silver Spring, MD, USA) (Kononen et al, 1998). Cores of
0.6mm thickness were sampled in quadruplicate for each case.
Immunohistochemistry
Sections of 4mm thickness were cut from all TMAs for the
purpose of immunohistochemistry.. Sections were immunostained
with CXCL1 (R&D Systems, Abingdon, UK, cat# MAB275), CXCR1
(Biosource, Invitrogen, Carlsbad, CA, USA, cat# AHR1522X),
CXCR2 (Biosource, cat# AHR1532X) and CXCL8 (Affinity Bio-
reagents, Golden, CO, USA, cat# PA1-32883) on an automated
platform (Bond system – Leica Microsystems, Bannockburn, IL,
USA). Briefly, cut sections were subjected to on-board dewaxing
and the following conditions: CXCL1 and CXCR2 – antigen
retrieval in tri-sodium citrate buffer (Bond Epitope Retrieval 1
solution) for 10min and 1:500 antibody dilution; CXCR1 –
antigen retrieval in EDTA buffer (Bond Epitope Retrieval 2
solution) for 20min and 1:4000 antibody dilution; CXCL8 – no
antigen retrieval and 1:500 antibody dilution. Detection of the
antibody–antigen complex was achieved using a polymer-based
kit (Bond Refine) with DAB as the chromogen. All sections
were counterstained with haematoxylin. Negative controls were
included for all sections by omitting the primary antibody and
positive controls used included samples of tonsil and colonic
adenocarcinoma.
Immunohistochemical assessment
Two reviewers who were blinded to the clinico-pathological details
and clinical outcome of the cohort performed the immunohisto-
chemical evaluation of the staining independently. Cores with at
least 50% of the tissue preserved after sectioning were included in
the study. The TMAs were stained for expression of the CXC-
chemokine receptors CXCR1 and CXCR2, and the ligands CXCL1
and CXCL8. Cytoplasmic epithelial staining of the tissue cores for
CXCR1, CXCR2 and CXCL1 was detected and the degree of
expression was recorded. This was determined by a combined
score comprising the percentage of cells with staining (none¼0;
o10%¼1; 10–50%¼2; 51–80%¼3; 480%¼4) and the inten-
sity of the staining (none¼0; weak¼1; moderate¼2; strong¼3).
The product of both values was described as the immunoreactivity
score (IRS), and used for the final analysis (Remmele and Stegner,
1987); this method has been used in similar studies evaluating
chemokine immunohistochemistry expression (Eck et al, 2003;
Jiang et al, 2006). Colorectal cell epithelial CXCL8 staining was
minimal and, therefore, formal evaluation was not performed.
Immunostaining of the surrounding infiltrating inflammatory
cells was also observed, in relation to both malignant and normal
tissue. Although the epithelial tissue had shown negligible staining
for CXCL8, this infiltrate demonstrated clear differential staining,
particularly within the tumour cores. Consequently we evaluated
CXCL8 expression within these inflammatory cells, in order to
explore the clinical implications of the differences in staining.
Because of the limited size of the tissue cores and as the
immunostaining in the inflammatory cells appeared homogenous,
the scoring system used for the colorectal cells was deemed
inappropriate for the infiltrate. Therefore, each core was denoted
as either negative or positive for inflammatory cell CXCL8
expression. Only two of the cases evaluated had no visible
inflammatory cells within their available cores; these were,
therefore, regarded as negative. Cases with at least two positive
staining cores were considered positive in the final analysis. There
was strong correlation between the two scorers, and in discrepant
cases, a consensus was reached after a joint review.
There was some sample loss through damage to the cores during
TMA construction and sectioning, a well-recognised limitation of
the procedure. Tissue damage rates ranging from 15 to 33% have
been reported (Schraml et al, 1999; Mucci et al, 2000; Richter et al,
2000), and this study was able to recover 72% of cases for
evaluation of the various markers, a proportion thus comparable
to the literature.
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Patient data had been collected via a centralised trial co-ordinating
office during the period of the clinical study and stored
electronically. Statistical analysis was performed via the SPSS 17
and SPSS 18 software packages (SPSS, Chicago, IL, USA).
Differences between the mean IRS scores of the malignant and
normal colorectal epithelium samples were compared using the
paired Student’s t-test. Correlation of CXC-chemokine and
receptor expression was performed using Spearman rank correla-
tion test. Association between the IRS scores and clinico-
pathological variables was assessed using w
2-test and Fisher’s
exact test as appropriate. Survival rates were compared using the
Kaplan–Meier curves, and univariate survival analysis performed
using the log-rank test. Multivariate survival analysis was
performed through Cox regression analysis. A P-value of o0.05
was considered significant in all analyses performed.
RESULTS
Clinical-pathological features
The median age of the patients at the time of surgery was 64 years
(range 35–80 years). Males (n¼149) and females (n¼105) were
included in the study cohort and the median duration of follow up
was 68 months (range 11–105 months). In total, 71 patients had
rectal carcinoma, whereas 183 had colonic carcinoma. There was a
predominance of patients with stage II disease among the patients
(163 patients with stage II and 91 patients with stage III disease).
Table 1 shows the clinico-pathological demographics of the patient
cohort, along with the incidence of recurrence and survival status
in the group.
Comparison of CXCR1, CXCR2, CXCL1 and CXCL8
expression within normal and malignant colorectal tissue
The tissue specimens were evaluated for immunohistochemical
expression of the CXC-chemokines CXCL1 and CXCL8 and their
receptors CXCR1 and CXCR2 within the neoplastic and surround-
ing normal colorectal epithelium. Differences in the degree of
expression of these markers within the cytoplasm of colorectal
epithelial cells are illustrated in Figure 1A. The mean expression of
CXCR1, CXCR2 and CXCL1 for each case was classified as absent
or weak (IRS 0–3), moderate (IRS between three and nine) and
strong (IRS nine and above) as has been previously described
(Jiang et al, 2006). All the three markers showed predominantly
weak to moderate expression within normal colorectal epithelium;
conversely moderate to strong expression of each marker was
exhibited by the colorectal tumour epithelium (Supplementary
Table S1). Comparison of the mean IRS scores for CXCR1,
CXCR2 and CXCL1 in malignant and non-malignant tissue
confirmed higher expression of each chemokine marker in the
tumour epithelium relative to adjacent normal colorectal tissue
(Figure 2A). Additionally, correlation of the chemokine/receptor
expression within the malignant epithelium demonstrated a
modest, but statistically significant correlation between the
expression of CXCL1 and its receptor CXCR2 in the cohort of
patients (r¼0.263; Po0.001; Supplementary Table S2).
There was no meaningful immunostaining for CXCL8 within the
malignant or normal colorectal epithelium and this was, therefore,
not included in the epithelial tissue analysis; however, we detected
a significant and differential staining of CXCL8 within the
infiltrating inflammatory cells in the tissue sections (Figure 1B).
The majority of the tumour cores (65.4%) expressed positive
CXCL8 immunoreactivity within the tumour-associated inflam-
matory infiltrate. Conversely, 95.9% of the normal colorectal tissue
cores had no detectable CXCL8 expression within their infiltrating
inflammatory cells (Figure 2B).
Association between CXCR1, CXCR2, CXCL1 and CXCL8
expression and clinico-pathological factors
The association between CXCR1, CXCR2 and CXCL1 and CXCL8
expression in the tumour tissue and the various clinico-
pathological features of the study cohort is provided in Table 2.
We observed a significantly higher level of CXCR1 epithelial
expression in rectal cancer tissue compared with colon, with
18.6% of rectal tumour cases showing strong expression compared
with 7.3% of colon cancer cases (P¼0.033). There was no
significant difference in epithelial expression of the other markers
between tumour sites. Although there was no statistically
significant correlation between disease stage and neoplastic
epithelial expression of the chemokine markers, a higher propor-
tion of stage II patients had CXCL8-positive inflammatory cell
infiltrate within tumour cores, compared with stage III patients
(P¼0.031).
No association was found between tumour epithelial immuno-
staining for CXCR1, CXCR2 and CXCL1 or the tumour infiltrate
expression of CXCL8 and age at diagnosis, disease stage,
pathological grade or patient gender. Statistical analysis was
performed using w
2-test or Fisher’s exact test, as appropriate.
Association with clinical outcome
The primary objective of the clinical trial was to investigate the
impact of 16 weeks of adjuvant 5FU chemotherapy on the clinical
outcome of the patient cohort. In this analysis, there was no
significant difference between the treatment and observation arms
with respect to relapse-free and overall survival (Supplementary
Figure S1). The median RFS and overall survival in each treatment
arm were not reached at the time of analysis, and there was no
Table 1 Clinicopathologic details of patient cohort
No. of patients (n¼254) %
Age (years)
Median 64
Range 35–80
Gender
Male 149 58.7
Female 105 41.3
Tumour site
Colon 183 72.0
Rectum 71 28.0
UICC stage
Stage II 163 64.2
Stage III 91 35.6
Histological grade
I 19 6.3
II 197 77.6
III 30 11.8
Not stated 9 3.5
Received adjuvant treatment
Yes 127 50.0
No 127 50.0
Recurrence
Yes 163 64.2
No 91 34.8
Status at last review
Alive 148 58.2
Dead-all causes 106 41.8
Dead-from CRC 85 33.5
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curves (P¼0.23 and P¼0.38, respectively, log-rank test).
Additionally, in the current study the prognostic significance of
CXC-chemokine ligand and receptor expression within CRC tissue
was also determined, using univariate and multivariate survival
analyses. Univariate analysis of the entire cohort (Table 3) showed
that disease stage (Po0.001), and interestingly, expression of
CXCL8 within the tumour inflammatory infiltrate (Po0.001) was
the only significant factors impacting on recurrence-free survival
(RFS). The Kaplan–Meier survival curve (Figure 3) demonstrated
that patients with positive CXCL8 staining in this tumour infiltrate
had a significantly improved RFS (median survival not reached)
compared with patients with negative staining (median survival
69 months; 95% CI: 37.7–100.3, Po0.001 log-rank test). The
degree of malignant epithelial tissue expression of the markers
did not correlate with patient survival in the overall cohort, and
co-expression did not improve their prognostic value (data not
shown). However, further subgroup univariate analysis of stage III
patients indicated a significant association between higher CXCL1
expression in the tumour samples and poorer RFS (P¼0.041). The
Kaplan–Meier curve illustrates the poorer outcome of patients
with strong CXCL1 immunostaining, relative to moderate or
weak/absent expression (Supplementary Figure S2).
Multivariate analysis using Cox regression proportional hazard
analysis confirmed disease stage and tumour infiltrate CXCL8
expression as independent predictors of RFS across the study
cohort (Table 4). CXCL8-positivity in the tumour infiltrate was
associated with a statistically significant reduction in the risk of
disease recurrence (hazard ratio: 0.55, CI: 0.36–0.85, Po0.001).
DISCUSSION
In this study, we have conducted an extensive analysis of CXC-
chemokine and its receptor expression in CRC tissue using a tissue
microarray comprising 254 stage II and stage III biopsies.
Intermediate to strong expression of CXCL1, CXCR1 and CXCR2
was concurrently detected in the epithelium of stage II and stage
III CRC tumours. In contrast, patient-matched normal epithelial
tissue demonstrated predominantly weaker expression of these
markers. Although CXCL1 expression has previously been detected
in CRC epithelium (Cuenca et al, 1992; Baier et al, 2005; Wen et al,
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Figure 1 Immunohistochemical characterisation of CXC-chemokine and its receptor expression in colorectal tissue. (A) Representative high-powered
images (magnification  200) illustrating weak (left panel) and strong (right panel) immunoreactivity to antibodies used to characterize the expression of
CXCR1, CXCR2 and CXCL1 in colorectal biopsy tissue. (B) Representative low-powered images showing differential expression of CXCL8 within the
inflammatory cells surrounding the colorectal epithelial tissue.
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Figure 2 Quantitative comparison of CXC-chemokine and its receptor expression in colorectal tissue. (A) Bar graphs presenting the relative
immunoreactivity score calculated for CXCR1, CXCR2 and CXCL1 in normal and malignant colorectal epithelial cells. The mean expression in tumor and
normal tissues was compared using Student’s t-test. Malignant tissue showed significantly higher levels of expression of all three markers in comparison to the
surrounding normal tissue; ***Po0.001. (B) Bar graph illustrating the number of positive cases in which CXCL8 immunoreactivity was detected in the
inflammatory cells surrounding the normal and malignant epithelial cells in the colorectal tissue. The majority of the cores with normal epithelium are absent
for CXCL8 expression within the inflammatory infiltrate. In contrast, a greater number of cores with malignant epithelium show inflammatory cell CXCL8
positivity.
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CXCL1 and the expression of its biological target, the CXCR2
receptor within the tumour samples (Po0.001). Therefore, our
study is the first to indicate concurrent ligand and receptor
expression in CRC tissue, suggesting a continuous autocrine
CXC-chemokine signalling stimulus within these cells.
It is noteworthy that no significant CXCL8 immunoreactivity
was detected in the CRC tissue, despite using similar approaches
that were previously successful in assessing CXCL8 expression in
prostate cancer epithelium (Murphy et al, 2005). Previous studies
that have characterized CXCL8 expression in CRC tissue have
often been conducted in a more advanced disease stage and used
techniques other than immunohistochemistry (Ueda et al, 1994;
Chung and Chang, 2003; Csiszar et al, 2004; Erreni et al, 2009),
however, almost two-thirds of our cohort comprised stage II CRC.
Therefore, it is conceivable that the good prognosis of this patient
selection may explain the absence of CXCL8 immunoreactivity in
the epithelial cells. Instead, we postulate that the expression of
CXCL8 may become detectable and especially significant in a more
advanced disease stage, indicative of the tumour-promoting effects
Table 2 Relationship between clinico-pathological factors and expression of CXC-chemokine biomarkers in the epithelial cells or immune-infiltrate
of colorectal tissue
CXCR1 expression
(n¼210)
CXCR2 expression
(n¼189)
CXCL1 expression
(n¼213)
Inflammatory cell CXCL8
expression (n¼228)
Weak
(n¼28)
Moderate
(n¼160)
Strong
(n¼22) P-value
Weak
(n¼18)
Moderate
(n¼120)
Strong
(n¼51) P-value
Weak
(n¼30)
Moderate
(n¼162)
Strong
(n¼21) P-value
Negative
(n¼79)
Positive
(n¼149) P-value
Age
o64 14 (6.7%) 78 (37.1%) 10 (4.8%) 8 (4.2%) 55 (29.1%) 28 (14.8%) 17 (8.0%) 74 (34.7%) 13 (6.1%) 39 (17.1%) 72 (31.6%)
464 14 (6.7%) 82 (39.0%) 12 (5.7%) 0.946 10 (5.3%) 65 (34.4%) 23 (12.2%) 0.525 13 (6.1%) 88 (41.3%) 8 (3.8%) 0.244 40 (17.5%) 77 (33.8%) 0.890
Gender
Male 20 (9.5%) 92 (43.8%) 13 (6.2%) 12 (6.3%) 71 (37.6%) 30 (15.9%) 17 (8.0%) 95 (44.6%) 12 (5.6%) 43 (18.9%) 92 (40.4%)
Female 8 (3.8%) 68 (32.4%) 9 (4.3%) 0.383 6 (3.2%) 49 (25.9%) 21 (11.1%) 0.821 13 (6.1%) 67 (31.5%) 9 (4.2%) 0.975 36 (15.8%) 57 (25.0%) 0.322
Stage
II 16 (7.6%) 103 (49.0%) 16 (7.6%) 11 (5.8%) 72 (38.1%) 39 (20.6%) 18 (8.5%) 105 (49.3%) 14 (6.6%) 43 (18.9%) 103 (45.2%)
III 12 (5.7%) 57 (27.1%) 6 (2.9%) 0.512 7 (3.7%) 48 (25.4%) 12 (6.3%) 0.114 12 (5.6%) 57 (26.8%) 7 (3.3%) 0.856 36 (15.8%) 46 (20.2%) 0.031
Site
Rectum 5 (2.4%) 43 (20.5%) 11 (5.2%) 6 (3.2%) 28 (14.8%) 12 (6.3%) 8 (3.8%) 48 (22.5%) 2 (0.9%) 16 (7.0%) 47 (20.6%)
Colon 23 (11.0%) 117 (55.7%) 11 (5.2%) 0.033 12 (6.3%) 92 (48.7%) 39 (20.6%) 0.646 22 (10.3%) 114 (53.5%) 19 (8.9%) 0.150 63 (27.6%) 102 (44.7%) 0.087
Received chemotherapy
No 15 (7.1%) 75 (35.7%) 13 (6.2%) 8 (4.2%) 53 (28.0%) 24 (12.7%) 15 (7.0%) 81 (38.0%) 11 (5.2%) 46 (20.2%) 71 (31.1%)
Yes 13 (6.2%) 85 (40.5%) 9 (4.3%) 0.492 10 (5.3%) 67 (35.4%) 27 (14.3%) 0.940 15 (7.0%) 81 (38.0%) 10 (4.7%) 0.979 33 (14.5%) 78 (34.2%) 0.164
Values shown in italic are not significant.
Table 3 Univariate survival analysis for epithelial CXC-chemokine expression
All patients (n¼254) Stage II patients (n¼163) Stage III patients (n¼91)
Recurrence-free
survival
Overall
survival
Recurrence-free
survival
Overall
survival
Recurrence-free
survival
Overall
survival
Recurrences/
no. of patients
log-rank
(P)
Deaths/
no. of
patients
log-rank
(P)
Recurrences/
no. of patients
log-rank
(P)
Deaths/
no. of
patients
log-rank
(P)
Recurrences/
no. of patients
log-rank
(P)
Deaths/
no. of
patients
log-rank
(P)
Tumour stage
II 40/163 51/163
III 51/91 o0.001 55/91 o0.001
Tumour epithelial CXCR1
Absent/weak 7/28 9/28 6/19 7/19 1/9 2/9
Moderate 63/160 0.379 69/160 0.586 59/103 0.156 65/103 0.146 4/57 0.675 4/57 0.106
Strong 10/22 11/22 10/14 11/14 0/8 0/8
Tumour epithelial CXCR2
Absent/weak 8/18 9/18 8/13 9/13 0/5 0/5
Moderate 45/120 0.748 47/120 0.482 40/74 0.879 42/74 0.880 5/46 0.314 5/46 0.698
Strong 18/51 25/51 18/36 23/36 0/15 2/15
Tumour epithelial CXCL1
Absent/weak 9/30 9/30 8/14 9/14 1/16 0/16
Moderate 63/162 0.546 71/162 0.409 61/107 0.585 66/107 0.628 2/55 0.041 5/55 0.061
Strong 8/21 9/21 6/14 7/14 2/7 2/7
Tumour inflammatory infiltrate CXCL8
Negative 42/79 39/79 38/50 36/50 4/29 3/29
Positive 42/149 o0.001 58/149 0.150 41/99 o0.001 54/99 0.029 1/50 0.040 4/50 0.806
Values shown in italic are not significant.
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and CXCR2 expression in the tumour epithelium provides a
functional compensation for the absence of CXCL8. Alternative
and more quantitative methods of detection of CXCL8, such
assessment of gene expression by PCR, may be of added utility to
further investigate these and other chemokines and receptors.
Although extensive analysis was performed, we found no
association between CXCR1 and CXCR2 expression and patient
outcome in the overall cohort (stage II and stage III tumours).
However, a univariate analysis did identify a significant association
between elevated CXCL1 expression and poorer relapse-free
survival in stage III CRC patients. (P¼0.04). Although not
addressed in this study, de-regulated CXCL1 and CXCL8 signalling
has been associated with increased cell proliferation and migratory
responses in CRC cells (Brew et al, 2000; Itoh et al, 2005).
Increased secretion of CXCL1 and CXCL8 from tumour epithelium
has also been reported to induce angiogenesis in gastro-intestinal
cancers (Heidemann et al, 2003; Wang et al, 2006; Matsuo et al,
2009). Furthermore, in Hodgkins’ disease, CXCL1 chemoattraction
of inflammatory cells contributes to a complex tumour–host
cellular interplay that can result in suppression of cell-mediated
cellular immune response and consequently, tumour progression
(Skinnider and Mak, 2002). Therefore, it is conceivable that,
these individual or combined functions may contribute to the
association of CXCL1 expression with an unfavourable outcome
in stage III CRC. Understanding the impact of these potential roles
of CXCL1 to adverse prognosis merits further studies in CRC
collections that include a greater overall number of stage III and/or
stage IV tumours.
The previous observation of stage dependence in relation to the
prognostic potential of a specific CXC-chemokine’s expression
raises several important considerations. The impact of CXC-
chemokine signalling on clinical outcome is likely to be influenced
by numerous factors, including the genetic background of the
tumour. For example, increased CXCR2 signalling reportedly
underpins oncogenic Ras-induced senescence in p53 wild-type
tumour cells (Acosta et al, 2008), but the effects of oncogenic
Ras-induced CXC-chemokine signalling may have different effects,
for example, in cells harbouring abnormal p53 function. Further-
more, we have shown that stress-induced expression of CXC-
chemokines and the magnitude of their signalling effects are more
significant in amplitude and duration in PTEN-deficient prostate
cancer cells compared with the PTEN-wild-type counterparts
(Maxwell and Waugh, unpublished observations). Although
unconfirmed, it is plausible that our patient cohort with stage III
disease may have different underlying genetic defects than stage II
patients; indeed, this concept is currently under investigation
through a number of clinical studies (Tejpar et al, 2010). Under
these circumstances, the increase in CXCL1/CXCR2 signalling may
underpin a more adverse clinical impact. More studies in larger
cohorts, together with a comprehensive characterisation of the
genetic constitution within the tumours would be useful to further
explore the merits of our observation.
As alluded to, CXC-chemokine expression within the surround-
ing tumour microenvironment, distinct from the cancer cell
epithelial expression, has been an additional area of investigation.
Perhaps the most intriguing observation in this study is the
identified impact of peritumoural inflammatory cell CXCL8
expression upon patient outcome. Indeed, positive CXCL8
inflammatory infiltrate expression resulted in enhanced relapse-
free survival relative to negative expression, with a hazard ratio
of 0.55. This is a considerable improvement in the outcome of a
group of patients with an already favourable prognosis (two-thirds
stage II disease), and was independent of disease stage on
multivariate analysis. Chemokines such as CXCL8 are known to
exert potent chemotactic influences on a range of inflammatory
cells, such as T cells, neutrophils and basophils (Oppenheim et al,
1991), the full implications of which are yet to be fully elucidated
and may be relevant to our findings. For example, the prognostic
significance of tumour-associated inflammatory cells in gastro-
oesophageal cancer is conflicting, with the role of infiltrating
macrophages and lymphocytes being reported as both favourable
and adverse in contradictory reports (Ma et al, 1999; Ohno et al,
2003; Koide et al, 2004; Deans et al, 2006). However, in general the
presence of increased tumour-related cellular infiltrate has been
associated with improved survival in CRC (Jass, 1986; Nielsen et al,
1999; Canna et al, 2005); nevertheless, there has been limited
characterisation of the expression of pro-inflammatory mediators,
including CXC-chemokines within these cells. Our study addressed
this question in relation to CXCL8 expression, and provides novel
clinical evidence linking such expression specifically within the
tumour infiltrate and within these well-defined disease stages to
improved patient outcome.
The good prognostic effect conferred by the infiltrate’s CXCL8
positivity most likely reflects the immune functions of this
chemokine and the anti-tumour role of the inflammatory cells.
Although CXCL8 is recognised for its ability to recruit immune
cells, the chemokine also induces neutrophil activation promoting
the respiratory burst characteristic of these cells. This triggers the
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Figure 3 Relapse-free survival of stage II and III CRC patients, based on
CXCL8 expression within the tumour inflammatory infiltrate. Kaplan–
Meier curve representing the recurrence-free survival of stage II and stage III
colorectal cancer patients. Samples were stratified on the basis of either
positive or negative CXCL8 immunoreactivity within the infiltrating immune
cells surrounding the tumor epithelium. Patients with a CXCL8 positive
infiltrate were shown to have an increased relapse-free survival with
the median interval not being reached. In contrast, patients with no
CXCL8 immunoreactivity had a median survival of 69 months (Po0.01;
log-ranks test).
Table 4 Multivariate survival analysis for epithelial- and immune infiltrate-
localized CXC-chemokine expression
Recurrence-free survival Overall survival
Hazard ratio 95% CI (P) Hazard ratio 95% CI (P)
UICC stage
Stage II 1 1.92–4.62 1 1.60–3.92
Stage III 2.98 (Po0.001) 2.50 (Po0.001)
Inflammatory infiltrate CXCL8
Negative 1 0.36–0.85 1 0.462–1.147
Positive 0.55 (P¼0.007) 0.728 (P¼0.171)
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can facilitate antitumour cytotoxicity (Schroder et al, 1990b).
Thus, the CXCL8 immunoreactivity detected within the tumour
infiltrate may correlate with increased activity of the immune
cells. This scenario has been predicted from an experimental
model of ovarian cancer in which elevated intra-tumoural
CXCL8 expression correlated with an increased infiltration of
neutrophils and macrophages and a decreased tumourigenicity
(Lee et al, 2000). This fascinating observation, therefore, justifies
the execution of larger cohort studies to validate our findings.
Characterisation of the underlying mechanisms that could explain
the observed survival benefit of CXCL8 in this context will also be
necessary.
In conclusion, this study demonstrates CXC-chemokine and its
receptor expression within CRC tissue. Expression of CXCL1 is
associated with a poor prognosis in stage III CRC. Conversely,
increased expression of CXCL8 in the inflammatory cell infiltrate
of the tumour tissue is associated with a favourable prognosis in
this cohort of stage II and stage III CRC tissues. Thus, we
demonstrate the potentially distinct effects of chemokine expres-
sion and signalling on tumour progression and clinical prognosis
within different compartments of the tumour microenvironment.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
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